B. Riley Issues Pessimistic Outlook for Verastem Earnings

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at B. Riley cut their Q2 2025 earnings per share (EPS) estimates for Verastem in a report released on Monday, April 28th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will earn ($0.56) per share for the quarter, down from their prior forecast of ($0.53). B. Riley has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. B. Riley also issued estimates for Verastem's Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.98) EPS, FY2026 earnings at ($1.21) EPS and FY2028 earnings at $0.99 EPS.

A number of other research analysts have also recently issued reports on the company. Jefferies Financial Group began coverage on Verastem in a research note on Thursday, April 10th. They set a "buy" rating and a $15.00 price objective on the stock. Royal Bank of Canada lowered their price objective on Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday, March 21st. StockNews.com lowered Verastem from a "hold" rating to a "sell" rating in a research note on Friday, April 18th. Mizuho decreased their target price on shares of Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, HC Wainwright increased their price target on shares of Verastem from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $13.89.

Verastem Price Performance

Shares of Verastem stock remained flat at $7.43 during trading on Thursday. 575,831 shares of the stock were exchanged, compared to its average volume of 1,037,330. The company has a market cap of $382.57 million, a P/E ratio of -2.33 and a beta of 0.57. The firm has a 50-day simple moving average of $6.23 and a 200-day simple moving average of $5.34. Verastem has a 12 month low of $2.10 and a 12 month high of $13.52. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77.

Verastem (NASDAQ:VSTM - Get Free Report) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.57).

Institutional Trading of Verastem

Institutional investors and hedge funds have recently bought and sold shares of the stock. Balyasny Asset Management L.P. purchased a new position in shares of Verastem in the 4th quarter valued at approximately $20,400,000. AIGH Capital Management LLC purchased a new stake in shares of Verastem in the 4th quarter worth about $13,778,000. Rosalind Advisors Inc. bought a new position in shares of Verastem in the 4th quarter worth about $4,653,000. Marshall Wace LLP purchased a new position in Verastem during the 4th quarter valued at about $4,103,000. Finally, Woodline Partners LP bought a new stake in Verastem during the fourth quarter worth about $3,742,000. 88.37% of the stock is currently owned by hedge funds and other institutional investors.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.